CEACAM5 and cancer: Patients with normal CEA and elevated sICAM-1 presented with a better outcome (overall 5-year survival rate 72.6%; cancer-related survival rate 86.0%) than patients with elevated CEA and sICAM-1low (overall 5-year survival rate 48.7%; cancer-related survival rate 59.1%).